AALL1331; Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467 NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Brief description of study

If you are the parent or guardian of a child diagnosed with B-lymphoblastic leukemia, your child may qualify to participate in a clinical trial investigating treatments with blinatumomab. The main goal of this study is to determine how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed).

Clinical Study Identifier: s15-00970
ClinicalTrials.gov Identifier: NCT02101853
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.